U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H11I3N2O5.C7H17NO5
Molecular Weight 839.1531
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEGLUMINE IOXITHALAMATE

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(C(=O)NCCO)=C(I)C(C(O)=O)=C1I

InChI

InChIKey=IFTFXKNYTWAOGK-WZTVWXICSA-N
InChI=1S/C12H11I3N2O5.C7H17NO5/c1-4(19)17-10-8(14)5(11(20)16-2-3-18)7(13)6(9(10)15)12(21)22;1-8-2-4(10)6(12)7(13)5(11)3-9/h18H,2-3H2,1H3,(H,16,20)(H,17,19)(H,21,22);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Molecular Formula C7H17NO5
Molecular Weight 195.2136
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C12H11I3N2O5
Molecular Weight 643.9396
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ioxitalamic acid is a contrast media, which was used as a meglumine salt under the name Telebrix for intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography). The drug is no longer available on the market.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
TELEBRIX

Approved Use

This medicinal product is for diagnostic use only. Contrast agent to be used for: intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography).
Diagnostic
TELEBRIX

Approved Use

This medicinal product is for diagnostic use only. Contrast agent to be used for: intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography).
Diagnostic
TELEBRIX

Approved Use

This medicinal product is for diagnostic use only. Contrast agent to be used for: intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography).
PubMed

PubMed

TitleDatePubMed
Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents.
2004 Feb
N-acetylcysteine attenuates iodine contrast agent-induced nephropathy in 5/6-nephrectomized rats.
2010
Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial.
2014
Resveratrol alleviates the cytotoxicity induced by the radiocontrast agent, ioxitalamate, by reducing the production of reactive oxygen species in HK-2 human renal proximal tubule epithelial cells in vitro.
2016 Jan
Patents

Patents

Sample Use Guides

The recommended doses are 1.0 ml/kg (Intravenous urography); 1 and 1.8 ml/kg (computed tomography of brain and computed tomography of the whole body, respectively); 40 ml (ventriculography); 4-8 ml (coronary angiography). The solution for injection contains 350 mg iode/ml.
Route of Administration: Intravenous
In Vitro Use Guide
Ioxitalamic acid was added to human basophils and mast cells isolated from lung, skin, and heart tissue at concentration of 0.1 to 0.5 mol/L (Telebrix preparation). The drug induced histamine release from basophils and histamine and tryptase release from human heart mast cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:17:56 GMT 2023
Edited
by admin
on Fri Dec 15 15:17:56 GMT 2023
Record UNII
5791GC9HSW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEGLUMINE IOXITHALAMATE
Common Name English
IOXITHALAMATE METHYLGLUCAMINE
Common Name English
IOXITALAMATE MEGLUMINE
WHO-DD  
Common Name English
Ioxitalamate meglumine [WHO-DD]
Common Name English
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, 5-ACETAMIDO-N-(2-HYDROXYETHYL)- 2,4,6-TRIIODOISOPHTHALAMATE (SALT)
Common Name English
MEGLUMINE IOXITALAMATE
Common Name English
Code System Code Type Description
FDA UNII
5791GC9HSW
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
CAS
29288-99-1
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
EVMPD
SUB14258MIG
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
ECHA (EC/EINECS)
249-544-2
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
DRUG BANK
DBSALT002569
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
PUBCHEM
23620195
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
MESH
C001694
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
RXCUI
29459
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID90951870
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
SMS_ID
100000085390
Created by admin on Fri Dec 15 15:17:56 GMT 2023 , Edited by admin on Fri Dec 15 15:17:56 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY